US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

California Resources

36.22

+0.81002.29%

Post-market: 36.220.00000.00%19:43 EDT

Volume:587.93K

Turnover:21.22M

Market Cap:3.28B

PE:7.84

High:36.47

Open:35.93

Low:35.11

Close:35.41

Loading ...

Overview Company News Filings

BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

California Resources Corporation Schedules First Quarter 2025 Earnings Conference Call

California Resources Cut to Neutral From Buy by Citigroup

Citigroup Downgrades California Resources to Neutral From Buy, Adjusts Price Target to $36 From $62

MT Newswires Live

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

California Resources price target lowered to $67 from $73 at Stephens

Press Release: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Press Release: LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

California Resources Price Target Maintained With a $68.00/Share by RBC Capital

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

California Resources Corp (CRC) Receives a Rating Update from a Top Analyst

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CRC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRC\",,,,,undefined,":{"symbol":"CRC","market":"US","secType":"STK","nameCN":"California Resources","latestPrice":36.22,"timestamp":1746216000000,"preClose":35.41,"halted":0,"volume":587926,"hourTrading":{"tag":"盘后","latestPrice":36.22,"preClose":36.22,"latestTime":"19:43 EDT","volume":83320,"amount":3017857.9,"timestamp":1746229432205},"delay":0,"floatShares":89794414,"shares":90646665,"eps":4.62,"marketStatus":"Not Yet Opened","change":0.81,"latestTime":"05-02 16:00:00 EDT","open":35.93,"high":36.47,"low":35.105,"amount":21220836.2144,"amplitude":0.038548,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.62,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1415854800000,"exchange":"NYSE","adjPreClose":35.41,"dividendRate":0.038515,"preHourTrading":{"tag":"盘前","latestPrice":38,"preClose":35.41,"latestTime":"09:19 EDT","volume":205,"amount":7353.080835000001,"timestamp":1746191967308},"postHourTrading":{"tag":"盘后","latestPrice":36.22,"preClose":36.22,"latestTime":"19:43 EDT","volume":83320,"amount":3017857.9,"timestamp":1746229432205},"volumeRatio":0.8506146266197995,"impliedVol":0.5816,"impliedVolPercentile":0.908},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRC\",,,,,undefined,":{"symbol":"CRC","floatShares":89794414,"roa":"7.63%","roe":"13.06%","lyrEps":4.741488,"volumeRatio":0.8506146266197995,"shares":90646665,"dividePrice":1.395,"high":36.47,"amplitude":0.038548,"preClose":35.41,"low":35.105,"week52Low":30.97,"pbRate":"0.93","psRate":"1.12","week52High":60.41,"institutionHeld":0,"latestPrice":36.22,"eps":4.62,"divideRate":0.038515,"volume":587926,"delay":0,"ttmEps":4.62,"open":35.93,"prevYearClose":51.89,"prevWeekClose":35.62,"prevMonthClose":34.51,"prevQuarterClose":43.97,"fiveDayClose":35.62,"twentyDayClose":40.58,"sixtyDayClose":48.16,"earningDate":1746460800000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526131059","title":"BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2526131059","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526131059?lang=en_us&edition=fundamental","pubTime":"2025-04-10 01:44","pubTimestamp":1744220640,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo  plus Yervoy .The regulatory body approved Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients  with unresectable or metastatic microsatellite instability-high  or mismatch repair deficient  colorectal cancer .Please note that Opdivo , as a single agent or in combination with Yervoy, was previously granted accelerated approval in MSI-H/dMMR CRC in adult and pediatric patients  who have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.The latest FDA approval converts this second-line indication to full approval for Opdivo monotherapy and expands the indication for Opdivo plus Yervoy into the first-line setting.Shares of BMY have risen 7.9% in the past year against the industry’s decline of 20%.This randomized, multicenter, open-label study is evaluating Opdivo plus Yervoy compared to Opdivo alone or chemotherapy in patients with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmy-gets-fda-nod-label-174400443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","BK4588","IE00BJJMRZ35.SGD","LU0321505439.SGD","LU1868836757.USD","LU2065169927.USD","CRC","LU0306806265.USD","LU1032466523.USD","LU1291159041.SGD","ANIP","LU2065171402.SGD","LU1261432733.SGD","BMY","BK4534","LU1670710661.SGD","LU2065170008.USD","LU1559883803.SGD","LU0868494617.USD","LU2125154778.USD","LU0456855351.SGD","LU1093756168.USD","BK4139","IE00BFTCPJ56.SGD","LU2125154935.USD","LU1585245621.USD","LU1670711123.USD","IE00BSNM7G36.USD","LU0061475181.USD","LU1718418525.SGD","IE00BFXG1179.USD","LU2242652126.USD","BK4559","BK4532","LU0306807586.USD","LU0114720955.EUR","LU0985481810.HKD","LU1670711040.USD","LU1323610961.USD","LU0096364046.USD","LU0266512127.USD","LU0321505868.SGD","IE0002141913.USD","LU2065171311.SGD","BK4585","LU1989771016.USD","LU2360032135.SGD","LU0225771236.USD","FOLD"],"gpt_icon":0},{"id":"2526399577","title":"FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2526399577","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526399577?lang=en_us&edition=fundamental","pubTime":"2025-04-09 22:58","pubTimestamp":1744210733,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration  on Tuesday approved Bristol Myers Squibb& Co’s  Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients  with unresectable or metastatic microsatellite instability-high  or mismatch repair deficient  colorectal cancer .The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User Fee Act goal date.Also Read: Europe Approves Bristol Myers’ Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer. Opdivoas a single agent, or in combination withYervoy, was previously granted accelerated approval in MSI-H/dMMR CRC adult and pediatric patients  that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.Price Action: BMY stock is down 5.31% at $50.25 at the last check on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-bristol-myers-opdivo-145853592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","LU0306806265.USD","IE00BFXG1179.USD","LU0456855351.SGD","LU1989771016.USD","BK4559","LU2360032135.SGD","LU2133065610.SGD","MYE","LU1670710661.SGD","LU0225771236.USD","LU0306807586.USD","LU0321505868.SGD","BK4126","LU0321505439.SGD","LU0882574055.USD","BK4211","LU1093756168.USD","ORR","CRC","LU1074936037.SGD","LU1032466523.USD","LU0985481810.HKD","BK4213","BK4588","LU0114720955.EUR","LU1670711123.USD","LU1718418525.SGD","LU1323610961.USD","LU1868836591.USD","IE00B2B36J28.USD","LU1291159041.SGD","IE00BFTCPJ56.SGD","LU0061475181.USD","LU0225284248.USD","LU1571399168.USD","LU1670711040.USD","BK4532","BMY","LU1868836757.USD","IE00BJJMRZ35.SGD","LU1868836914.USD","PFS","LU2242646821.SGD","LU1868837136.USD","LU2125154778.USD","BK4534","LU0266512127.USD","IE00BSNM7G36.USD","BK4585"],"gpt_icon":0},{"id":"2526840536","title":"U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840536","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840536?lang=en_us&edition=fundamental","pubTime":"2025-04-09 03:36","pubTimestamp":1744140960,"startTime":"0","endTime":"0","summary":"Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo monotherapy across all lines of therapy 1. The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date. In the CheckMate-8HW trial, Opdivo plus Yervoy demonstrated a 38% reduction in the risk of disease progression or death vs. Opdivo monotherapy in immunotherapy-nave patients across all lines of therapy .1 Assessing the dual primary endpoint of PFS, the trial demonstrated that median PFS was not reached with Opdivo plus Yervoy  and was 39.3 months with Opdivo monotherapy .1 PFS rates at 12-, 24-, and 36-months were also numerically higher","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-approves-193600303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1718418525.SGD","LU2242646821.SGD","LU1989771016.USD","PFS","BK4534","LU1670711123.USD","BK4211","BK4195","IE00BFTCPJ56.SGD","CRC","LU1032466523.USD","LU0225771236.USD","LU1868836757.USD","LU1670711040.USD","BK4532","LU0114720955.EUR","LU0868494617.USD","LU1670710588.SGD","LU0225284248.USD","CRT","LU1074936037.SGD","LU2133065610.SGD","LU1868837136.USD","HSCT","LU1670710661.SGD","LU2242652126.USD","LU1585245621.USD","IE0002141913.USD","BK4132","LU0985481810.HKD","BK4124","OS","IE00B2B36J28.USD","HCC","LU1868837300.USD","BK4144","IE0009355771.USD","IE00BSNM7G36.USD","BMY","BK4006","LU1261432733.SGD","TEN","LU0061475181.USD","LU1093756325.SGD","ORR","VOD","LU1323610961.USD","LU0237698245.USD","BK4581","LU1093756168.USD"],"gpt_icon":0},{"id":"2525431540","title":"California Resources Corporation Schedules First Quarter 2025 Earnings Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2525431540","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525431540?lang=en_us&edition=fundamental","pubTime":"2025-04-07 21:00","pubTimestamp":1744030800,"startTime":"0","endTime":"0","summary":"LONG BEACH, Calif., April  07, 2025  (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) plans to release its first quarter 2025 financial results on Tuesday, May 6th after market close. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056779/0/en/California-Resources-Corporation-Schedules-First-Quarter-2025-Earnings-Conference-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC"],"gpt_icon":0},{"id":"2525601031","title":"California Resources Cut to Neutral From Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2525601031","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525601031?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:22","pubTimestamp":1744028520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 08:22 ET (12:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC"],"gpt_icon":0},{"id":"2525017521","title":"Citigroup Downgrades California Resources to Neutral From Buy, Adjusts Price Target to $36 From $62","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017521","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017521?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:05","pubTimestamp":1744027537,"startTime":"0","endTime":"0","summary":"California Resources (CRC) has an average rating of buy and mean price target of $64.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRC"],"gpt_icon":0},{"id":"2525017693","title":"Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017693","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017693?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, April  07, 2025  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056677/0/en/Adagene-to-Present-at-Stifel-s-2025-Virtual-Targeted-Oncology-Forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRC","LU0456854461.SGD","MSS","SF","LU0266512127.USD","BK4213","BK4127","BK4113","FET","BK4179","ADAG"],"gpt_icon":0},{"id":"2524537702","title":"California Resources price target lowered to $67 from $73 at Stephens","url":"https://stock-news.laohu8.com/highlight/detail?id=2524537702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524537702?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:40","pubTimestamp":1743680442,"startTime":"0","endTime":"0","summary":"Stephens lowered the firm’s price target on California Resources (CRC) to $67 from $73 and keeps an Overweight rating on the shares. The firm is ad...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/california-resources-price-target-lowered-to-67-from-73-at-stephens?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/california-resources-price-target-lowered-to-67-from-73-at-stephens?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRC"],"gpt_icon":0},{"id":"2524190703","title":"Press Release: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524190703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524190703?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:01","pubTimestamp":1743508860,"startTime":"0","endTime":"0","summary":"Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert in Europe. Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus. Strategic partnerships with industry leaders mark key progress. BERKELEY, Calif. and MAINZ, Germany, April 01, 2025  -- Mainz Biomed N.V.  , a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the year ended December 31, 2024, a summary on 2024 accomplishments, and an update on corporate developments for early 2025.-- Mainz Biomed and Thermo Fisher Scientific signed a collaboration. agreement for the development of the Company's next generation colorectal. enable Mainz Biomed and Thermo Fisher to jointly develop and potentially. commercialize Mainz Biomed's next generation colorectal cancer screening. product. The collaboration will harness Thermo Fisher's powerful. allow Mainz Biomed to develop ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USJW.SI","BK4022","BK4213","QID","PSQ","NVIW.SI","BK4232","QLD","CRC","LU0266512127.USD","LU0456854461.SGD","NQmain","MYNZ",".IXIC","TSYW.SI","MNQmain","TQQQ","USAW.SI","R","BK4139","SQQQ"],"gpt_icon":1},{"id":"2523919275","title":"Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening","url":"https://stock-news.laohu8.com/highlight/detail?id=2523919275","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523919275?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date. MADISON, Wis., March 31, 2025----Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening  test reported in studies to date.* FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.1 This performance means fewer unnecessary follow-up colonoscopies—up to a 40% reduction compared to the original Cologuard test2—and greater confidence in results.Colorectal cancer is highly treatable when caught early—survivable in about 90% of cases. Yet, nearly 48 million Americans remain unscreened.4 Routine screening not only detects colore","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exact-sciences-launches-cologuard-plus-100000989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4585","LU1861559042.SGD","BK4139","LU0266512127.USD","LU0456854461.SGD","BK4213","CRC","FIT","BK4588","LU0266013472.USD","EXAS","LU2324357040.USD","LU1861558580.USD"],"gpt_icon":0},{"id":"2522578495","title":"Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522578495","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522578495?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:45","pubTimestamp":1743162300,"startTime":"0","endTime":"0","summary":"REHOVOT, Israel, March  28, 2025  (GLOBE NEWSWIRE) --  Purple Biotech Ltd. (\"Purple Biotech\" or \"the Company\") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that se","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/28/3051307/0/en/Purple-Biotech-Announces-Three-Posters-Accepted-for-Presentation-at-the-2025-American-Association-for-Cancer-Research-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4107","CRC","LU0456854461.SGD","BK4213","LU0266512127.USD","BK4117"],"gpt_icon":0},{"id":"2522578540","title":"Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522578540","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522578540?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-1 resistant “hot” tumor patient population -. - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile -. - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 -. BOSTON, March 28, 2025  -- Sensei Biotherapeutics, Inc. , a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2024, and provided corporate updates.Among 21 evaluable PD-1 resistant “hot” tumor patients, the combination of solnerstotug + cemiplimab demonstrated a 14% ORR , which is almost 3x higher than historical PD-1 rechallenge response rates (≤5%), and a 62% DCR , suggesting meaningful disease control in resistant tumors.Two partial responses : one in a second MCC patient and one in a microsatellite instability-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensei-biotherapeutics-reports-full-2024-113000303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456854461.SGD","IE00B7SZL793.SGD","LU0266512127.USD","L","PRGS","IE0031619046.USD","IE00B19Z4B17.USD","LU2065731478.USD","LU0053666078.USD","BK4107","BK4097","CRS","BK4588","CRC","BK4139","BK4213","IE00B66KJ199.SGD","BK4585","SNSE","LU2065732104.USD","BK4006"],"gpt_icon":0},{"id":"2522520587","title":"Press Release: LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520587?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"-- Focused on the evaluation of strategic alternatives. -- Adopted a restructuring plan to extend capital resources, incurring a. reduction in workforce of 30% to support the evaluation of strategic. -- Phase 1 enrollment in LAVA-1266 clinical trial underway. \"LAVA's approach to maximize shareholder value in 2025 will focus on evaluating strategic options while continuing to enroll patients in our ongoing Phase 1 study of LAVA-1266, and supporting our pharma partnerships,\" said Steve Hurly, Chief Executive Officer of LAVA. \"The Phase 1 study of LAVA-1266 as a potential treatment for acute myeloid leukemia and myelodysplastic syndrome is progressing. Looking ahead, with a strong cash balance, we believe LAVA is well-positioned to unlock strategic opportunities, and we look forward to updating investors with our progress throughout the year.\". Designed to target CD123+ tumor cells for the treatment of hematological malignancies. -- Current Status: LAVA is enrolling patients in the second","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4504","BK4534","LU1914381329.SGD","CRC","IE00BVYPNV92.GBP","LU1066053197.SGD","LU1032466523.USD","LU0203345920.USD","LU1061106388.HKD","R","LU0058720904.USD","PD","LU1674673428.USD","LU2112291526.USD","LVTX","LU1280957306.USD","LU0882574055.USD","LU2430703095.HKD","LU1883839398.USD","LU2468319806.SGD","JNJ","LU1778281490.HKD","SG9999002232.USD","LU1059921491.USD","LU0306807586.USD","LU0320765646.SGD","PK","IE00B2B36J28.USD","LU1267930813.SGD","LU0122379950.USD","LU1674673691.USD","BK4588","LU1032955483.USD","BK4592","LU2592432038.USD","LU1894683264.USD","SG9999001176.SGD","LU1732799900.SGD","SGXZ57979304.SGD","BK4213","LU0466842654.USD","LU0170899867.USD","BK4023","IE0034235303.USD","LU2347655156.SGD","SG9999001176.USD","SG9999002224.SGD","SG9999011175.SGD"],"gpt_icon":1},{"id":"2522558078","title":"Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522558078","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522558078?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"– Initial clinical activity in a PD-1 resistant population, with an ORR almost three times higher than historical PD-1 rechallenge response rates, with data still maturing –。– One durable complete response in a Merkel Cell Carcinoma  patient and two partial responses , including one in a second MCC patient and one in a microsatellite instability-high  Colorectal Cancer  patient, all of whom were previously treated with and progressed on immunotherapy –。– All PD-1 resistant “hot” tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time –。The Phase 1 dose expansion trial is a multi-center, open-label, dose expansion study evaluating solnerstotug as monotherapy and in combination withLibtayo , Regeneron’s PD-1 inhibitor, in both a basket of “hot” tumorsthat typically respond to immunotherapy but have progressed on prior PD-1 therapy and a single “cold” tumor histology  that is typically unresponsive to immunotherapy.At the time of this da","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRS","BK4213","BK4231","SD","BK4080","BK4107","BK4139","IE00B19Z4B17.USD","MSS","BK4588","IE00B66KJ199.SGD","LU0456854461.SGD","LU0266512127.USD","BK4006","SITC","SNSE","BK4585","BK4161","LU1169589451.USD","BK4023","PD","LU1169590202.USD","CR","L","BK4113","IE0031619046.USD","RCC","CRC","IE00B7SZL793.SGD","PR","LU2065731478.USD","LU0053666078.USD"],"gpt_icon":0},{"id":"2522537272","title":"FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537272","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537272?lang=en_us&edition=fundamental","pubTime":"2025-03-28 03:00","pubTimestamp":1743102000,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx .The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors .Simultaneously, the drug was approved for adult and pediatric patients  with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET .Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.The approval came ahead of the target action date of April 3, 2025.The company is now focused on developing zanzalintinib, a next-generation oral TKI. In January 2025, results from an expansion cohort of the phase Ib/II STELLAR-001 study ev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-exelixis-cabometyx-label-190000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","IE00BFTCPJ56.SGD","BK4588","LU0096364046.USD","LU0237698245.USD","RCC","IE0002141913.USD","LU2125154935.USD","LU1718418525.SGD","BAYRY","LU0985481810.HKD","DTC","IE0009355771.USD","LU0225284248.USD","LU0882574055.USD","LU1670710588.SGD","LU1868836757.USD","LU1093756325.SGD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU2133065610.SGD","EXEL","BK4559","IE00B2B36J28.USD","BK4139","LU0321505868.SGD","IE00BFXG1179.USD","CRC","LU0456854461.SGD","LU1093756168.USD","LU0266512127.USD","IE00BKVL7J92.USD","LU1261432733.SGD","LU1868836914.USD","LU0321505439.SGD","LU2242646821.SGD","IE00BSNM7G36.USD","LU0306806265.USD","LU1323610961.USD","LU1670710661.SGD","BMY","LU0154236417.USD","LU1032466523.USD","LU1074936037.SGD","LU1989771016.USD","LU2360032135.SGD","LU1868837300.USD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2522519588","title":"California Resources Price Target Maintained With a $68.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522519588","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522519588?lang=en_us&edition=fundamental","pubTime":"2025-03-27 23:00","pubTimestamp":1743087600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 11:00 ET (15:00 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC"],"gpt_icon":0},{"id":"2522305361","title":"Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522305361","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522305361?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:01","pubTimestamp":1743080460,"startTime":"0","endTime":"0","summary":"2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report To","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/27/3050616/0/en/Mainz-Biomed-Enrolls-First-Patient-in-Its-eAArly-DETECT-2-Clinical-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","LU0456854461.SGD","CRC","BK4139","LU0266512127.USD","MYNZ"],"gpt_icon":0},{"id":"2522378635","title":"California Resources Corp (CRC) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2522378635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522378635?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:39","pubTimestamp":1743071945,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Scott Hanold maintained a Buy rating on California Resources Corp (CRC – Research Report) yesterday and set a price target of $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/california-resources-corp-crc-receives-a-rating-update-from-a-top-analyst-13?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/california-resources-corp-crc-receives-a-rating-update-from-a-top-analyst-13?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRC"],"gpt_icon":0},{"id":"2522935496","title":"Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935496","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935496?lang=en_us&edition=fundamental","pubTime":"2025-03-27 03:00","pubTimestamp":1743015600,"startTime":"0","endTime":"0","summary":"Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The company's upbeat performance can be attributed to its strong quarterly results, raised guidance and efforts to increase shareholders' returns.Last month, Exelixis announced a new share repurchase program of $500 million. Shares rallied following the announcement. Earlier, the company reported better-than-expected fourth-quarter results, which also drove the stock higher.Let’s delve deeper and analyze the company’s strengths and weaknesses to understand how to play the stock in such a scenario.Exelixis’ lead drug Cabometyx maintains its status as the leading tyrosine kinase inhibitor  for the treatment of renal cell carcinoma  in both the frontline immuno-oncology  +TKI market and the second-line monotherapy segment.Meanwhile, Exelixis collaborated with pharma giant Merck MRK to evaluate zanzalinti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-stock-rises-13-3-190000591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1934455277.USD","SG9999015358.SGD","LU0061475181.USD","IE00BFXG1179.USD","BK4516","LU1868836591.USD","BK4581","SG9999015341.SGD","LU1934455194.USD","LU2242646821.SGD","CRC","LU1093756325.SGD","LU1929549753.HKD","LU1037948897.HKD","BK4585","LU1670710588.SGD","BK4588","SG9999014542.SGD","LU1718418525.SGD","LU1868837300.USD","LU2133065610.SGD","SG9999014567.USD","LU1989772840.SGD","LU1989772923.USD","LU1974910355.USD","LU1037948541.HKD","LU1989771016.USD","LU1868837136.USD","IE00BJT1NW94.SGD","LU1323610961.USD","LU2023250504.SGD","BMY","EXEL","LU1670711123.USD","RCC","SGXZ57979304.SGD","LU1699723380.USD","LU0306806265.USD","LU1670710661.SGD","LU1941712264.USD","LU0266512127.USD","LU1057294990.SGD","LU1430594728.SGD","BK4550","LU0306807586.USD","MRK","BK4559","LU1868836914.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2522455332","title":"Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455332","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455332?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:29","pubTimestamp":1743010151,"startTime":"0","endTime":"0","summary":"Leap Therapeutics, Inc. presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab  in combination with bevacizumab and chemotherapy  compared to bevacizumab and chemotherapy .The trial enrolled patients with advanced microsatellite stable  colorectal cancer  who have received one prior systemic therapy for advanced disease.The updated analysis shared on Wednesday includes the overall response rate , an additional two months of patient follow-up for progression-free survival , and initial overall survival  data.As ofMarch 12, 2025, 34 patients remain on the study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm.In patients with highDKK1levels, the sirexatamab Experimental Arm has a statistically significant 32% higher ORR, 3.5 months longer PFS, and OS compared to the Control Arm:. In patients who had not received prior anti-VEGF therapy, the sirexatamab Experimental Arm has a statistically significant 22%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-leap-therapeutics-unveils-172911695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4113","IE00BMPRXN33.USD","LU0348723411.USD","MSS","BK4139","BK4211","BK4141","IE00BMPRXR70.SGD","ONC","BK4585","BK4588","BK4563","BK4097","LPTX","OS","PFS","BK4213","BK4609","LU0266512127.USD","BK4195","BK4543","LENZ","ORR","IE00BMPRXQ63.HKD","CRC","LU0456854461.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRC\",params:#limit:5,,,undefined,":[{"date":"2025-05-06","symbol":"CRC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.88,"defaultRemindTime":1746561600000,"name":null,"time":"Post Market","dateTimestamp":1746504000000,"actualEps":null},{"date":"2025-03-10","symbol":"CRC","amount":0.3875,"announcedDate":"2025-03-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"加州资源","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-21"},{"market":"US","date":"2025-03-03","symbol":"CRC","fiscalQuarterEnding":"2024/12","expectedEps":0.96,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":0.91},{"date":"2024-12-02","symbol":"CRC","amount":0.3875,"announcedDate":"2024-11-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-02","defaultRemindTime":1733149800000,"name":"加州资源","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-16","payableDate":"2024-12-02","currency":"USD","dateTimestamp":1733115600000,"payDate":"2024-12-16"},{"date":"2024-11-05","symbol":"CRC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/09","expectedEps":0.88,"defaultRemindTime":1730840400000,"name":null,"time":"Post Market","dateTimestamp":1730782800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRC\",market:\"US\",,,undefined,":[{"executeDate":"2021-11-30","recordDate":"2021-12-01","paymentDate":"2021-12-16","value":0.17,"currency":"USD"},{"executeDate":"2022-03-04","recordDate":"2022-03-07","paymentDate":"2022-03-16","value":0.17,"currency":"USD"},{"executeDate":"2022-05-31","recordDate":"2022-06-01","paymentDate":"2022-06-16","value":0.17,"currency":"USD"},{"executeDate":"2022-08-31","recordDate":"2022-09-01","paymentDate":"2022-09-16","value":0.17,"currency":"USD"},{"executeDate":"2022-11-30","recordDate":"2022-12-01","paymentDate":"2022-12-16","value":0.2825,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2143,"buy":0.5714,"hold":0.2143,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":14,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRC","date":"2025-05-02","current":8.536698,"percent":0.841463,"low":-4.759607,"twenty":0.682705,"median":3.875685,"eighty":7.879412,"high":29.507578,"avg":5.092011,"sd":6.540327,"marketCap":3209798407},"quantilePoints":[{"date":"2020-05-08","current":-4.177878,"twenty":-4.295208,"median":-0.162581,"eighty":1.420716,"marketCap":116980571},{"date":"2020-05-15","current":-2.626598,"twenty":-4.295208,"median":-0.184022,"eighty":1.393263,"marketCap":73544747},{"date":"2020-05-22","current":-2.538457,"twenty":-4.295208,"median":-0.192857,"eighty":1.375418,"marketCap":71076803},{"date":"2020-05-29","current":-2.344547,"twenty":-4.295208,"median":-0.200937,"eighty":1.357573,"marketCap":65647325},{"date":"2020-06-05","current":-3.543263,"twenty":-4.295208,"median":-0.20336,"eighty":1.341366,"marketCap":99211370},{"date":"2020-06-12","current":-2.661854,"twenty":-4.306077,"median":-0.205204,"eighty":1.323009,"marketCap":74531925},{"date":"2020-06-19","current":-2.644226,"twenty":-4.306077,"median":-0.207188,"eighty":1.282312,"marketCap":74038336},{"date":"2020-06-26","current":-0.036027,"twenty":-4.306077,"median":-0.209371,"eighty":1.269657,"marketCap":63300220},{"date":"2020-07-02","current":-0.033776,"twenty":-4.306077,"median":-0.209371,"eighty":1.250505,"marketCap":59343956},{"date":"2020-07-10","current":-0.032931,"twenty":-4.306077,"median":-0.209371,"eighty":1.226048,"marketCap":57860357},{"date":"2020-07-17","current":-0.009314,"twenty":-4.306077,"median":-0.209371,"eighty":1.210738,"marketCap":16364095},{"date":"2020-07-24","current":-0.006596,"twenty":-4.306077,"median":-0.209371,"eighty":1.196704,"marketCap":11589380},{"date":"2020-07-31","current":-0.006023,"twenty":-4.306077,"median":-0.209371,"eighty":1.180119,"marketCap":10583005},{"date":"2020-08-07","current":-0.00497,"twenty":-4.306077,"median":-0.209371,"eighty":1.169315,"marketCap":10137925},{"date":"2020-08-14","current":-0.003103,"twenty":-4.306077,"median":-0.209371,"eighty":1.155878,"marketCap":6330022},{"date":"2020-08-21","current":-0.002424,"twenty":-4.306077,"median":-0.209371,"eighty":1.137946,"marketCap":4945329},{"date":"2020-08-28","current":-0.002373,"twenty":-4.306077,"median":-0.209371,"eighty":1.121432,"marketCap":4841477},{"date":"2020-09-04","current":-0.00223,"twenty":-4.306077,"median":-0.209371,"eighty":1.109119,"marketCap":4549703},{"date":"2020-09-11","current":-0.001964,"twenty":-4.306077,"median":-0.209371,"eighty":1.099511,"marketCap":4005717},{"date":"2020-09-18","current":-0.002351,"twenty":-4.306077,"median":-0.209371,"eighty":1.086985,"marketCap":4796969},{"date":"2020-09-25","current":-0.002109,"twenty":-4.306077,"median":-0.209371,"eighty":1.080606,"marketCap":4302436},{"date":"2020-10-02","current":-0.002082,"twenty":-4.306077,"median":-0.209371,"eighty":1.069124,"marketCap":4248038},{"date":"2020-10-09","current":-0.001697,"twenty":-4.306077,"median":-0.209371,"eighty":1.046159,"marketCap":3461730},{"date":"2020-10-16","current":-0.001909,"twenty":-4.306077,"median":-0.209371,"eighty":1.039052,"marketCap":3894447},{"date":"2020-10-23","current":-0.001178,"twenty":-4.306077,"median":-0.209371,"eighty":1.018479,"marketCap":2403430},{"date":"2020-10-30","current":-0.547167,"twenty":-4.306077,"median":-0.210775,"eighty":1.002051,"marketCap":1116220000},{"date":"2020-11-06","current":-0.439133,"twenty":-4.306077,"median":-0.215303,"eighty":0.973809,"marketCap":949844819},{"date":"2020-11-13","current":-0.536975,"twenty":-4.306077,"median":-0.216571,"eighty":0.938992,"marketCap":1161476910},{"date":"2020-11-20","current":-0.590904,"twenty":-4.306077,"median":-0.218019,"eighty":0.914188,"marketCap":1278124520},{"date":"2020-11-27","current":-0.842442,"twenty":-4.306077,"median":-0.219356,"eighty":0.899442,"marketCap":1822202298},{"date":"2020-12-04","current":-1.030421,"twenty":-4.306077,"median":-0.22033,"eighty":0.892607,"marketCap":2228800905},{"date":"2020-12-11","current":-0.770408,"twenty":-4.306077,"median":-0.222998,"eighty":0.883681,"marketCap":1666393200},{"date":"2020-12-18","current":-0.808158,"twenty":-4.306077,"median":-0.223643,"eighty":0.862133,"marketCap":1748046466},{"date":"2020-12-24","current":-0.821255,"twenty":-4.306077,"median":-0.22525,"eighty":0.849685,"marketCap":1776375151},{"date":"2020-12-31","current":-0.908697,"twenty":-4.306077,"median":-0.227441,"eighty":0.838203,"marketCap":1965510779},{"date":"2021-01-08","current":-0.94375,"twenty":-4.306077,"median":-0.228513,"eighty":0.834376,"marketCap":2041331670},{"date":"2021-01-15","current":-0.96147,"twenty":-4.306077,"median":-0.230901,"eighty":0.834376,"marketCap":2079658713},{"date":"2021-01-22","current":-0.952225,"twenty":-4.306077,"median":-0.23285,"eighty":0.834376,"marketCap":2059661995},{"date":"2021-01-29","current":-0.889436,"twenty":-4.306077,"median":-0.235524,"eighty":0.834376,"marketCap":1923850949},{"date":"2021-02-05","current":-0.92449,"twenty":-4.306077,"median":-0.237422,"eighty":0.834376,"marketCap":1999671840},{"date":"2021-02-12","current":-0.980345,"twenty":-4.306077,"median":-0.239101,"eighty":0.834376,"marketCap":2120485347},{"date":"2021-02-19","current":-1.001531,"twenty":-4.306077,"median":-0.243277,"eighty":0.834376,"marketCap":2166311160},{"date":"2021-02-26","current":-1.012317,"twenty":-4.306077,"median":-0.244974,"eighty":0.834376,"marketCap":2189640664},{"date":"2021-03-05","current":-1.020791,"twenty":-4.307042,"median":-0.24807,"eighty":0.835141,"marketCap":2207970990},{"date":"2021-03-12","current":1.210636,"twenty":-4.307042,"median":-0.250121,"eighty":0.838203,"marketCap":2137982475},{"date":"2021-03-19","current":1.13845,"twenty":-4.307042,"median":-0.250121,"eighty":0.850388,"marketCap":2010503395},{"date":"2021-03-26","current":1.14883,"twenty":-4.306077,"median":-0.249299,"eighty":0.866271,"marketCap":2028833721},{"date":"2021-04-01","current":1.127127,"twenty":-4.306077,"median":-0.249299,"eighty":0.885408,"marketCap":1990506677},{"date":"2021-04-09","current":1.144112,"twenty":-4.307042,"median":-0.250121,"eighty":0.907117,"marketCap":2020501755},{"date":"2021-04-16","current":1.139866,"twenty":-4.307042,"median":-0.250121,"eighty":0.939757,"marketCap":2013002985},{"date":"2021-04-23","current":1.059188,"twenty":-4.307042,"median":-0.250121,"eighty":0.96943,"marketCap":1870526367},{"date":"2021-04-30","current":1.118163,"twenty":-4.307042,"median":-0.250121,"eighty":0.983134,"marketCap":1974675942},{"date":"2021-05-07","current":1.176194,"twenty":-4.307042,"median":-0.248184,"eighty":1.018359,"marketCap":2077159123},{"date":"2021-05-14","current":0.57973,"twenty":-4.307042,"median":-0.2454,"eighty":1.03654,"marketCap":2010503395},{"date":"2021-05-21","current":0.708505,"twenty":-4.307042,"median":-0.243788,"eighty":1.03654,"marketCap":2457096773},{"date":"2021-05-28","current":0.696973,"twenty":-4.307042,"median":-0.239857,"eighty":1.03654,"marketCap":2417103336},{"date":"2021-06-04","current":0.737816,"twenty":-4.307042,"median":-0.238075,"eighty":1.03654,"marketCap":2558746758},{"date":"2021-06-11","current":0.799561,"twenty":-4.307042,"median":-0.236957,"eighty":1.03654,"marketCap":2772878284},{"date":"2021-06-18","current":0.782984,"twenty":-4.307042,"median":-0.233507,"eighty":1.03654,"marketCap":2715387719},{"date":"2021-06-25","current":0.79836,"twenty":-4.307042,"median":-0.231347,"eighty":1.03654,"marketCap":2768712301},{"date":"2021-07-02","current":0.722921,"twenty":-4.307042,"median":-0.228622,"eighty":1.03654,"marketCap":2507088569},{"date":"2021-07-09","current":0.704181,"twenty":-4.307042,"median":-0.227828,"eighty":1.03654,"marketCap":2442099234},{"date":"2021-07-16","current":0.634508,"twenty":-4.307042,"median":-0.225451,"eighty":1.03654,"marketCap":2200472220},{"date":"2021-07-23","current":0.634988,"twenty":-4.307042,"median":-0.223277,"eighty":1.03654,"marketCap":2202138613},{"date":"2021-07-30","current":0.675351,"twenty":-4.307042,"median":-0.223131,"eighty":1.03654,"marketCap":2342115642},{"date":"2021-08-06","current":0.682705,"twenty":-4.307042,"median":-0.223131,"eighty":1.03654,"marketCap":2476853574},{"date":"2021-08-13","current":0.671872,"twenty":-4.307042,"median":-0.221697,"eighty":1.03654,"marketCap":2437551434},{"date":"2021-08-20","current":0.645015,"twenty":-4.307042,"median":-0.218296,"eighty":1.03654,"marketCap":2340114881},{"date":"2021-08-27","current":0.755828,"twenty":-4.307042,"median":-0.218003,"eighty":1.03654,"marketCap":2742143014},{"date":"2021-09-03","current":0.829402,"twenty":-4.307042,"median":-0.218003,"eighty":1.03654,"marketCap":3009070044},{"date":"2021-09-10","current":0.887629,"twenty":-4.307042,"median":-0.217706,"eighty":1.03654,"marketCap":3220319043},{"date":"2021-09-17","current":0.970457,"twenty":-4.307042,"median":-0.21731,"eighty":1.03654,"marketCap":3520816651},{"date":"2021-09-24","current":0.931864,"twenty":-4.307042,"median":-0.216391,"eighty":1.03654,"marketCap":3380802779},{"date":"2021-10-01","current":0.946534,"twenty":-4.307042,"median":-0.215187,"eighty":1.03654,"marketCap":3434024426},{"date":"2021-10-08","current":0.910424,"twenty":-4.306077,"median":-0.210775,"eighty":1.036368,"marketCap":3303017295},{"date":"2021-10-15","current":0.958947,"twenty":-4.306077,"median":-0.20336,"eighty":1.036368,"marketCap":3479058127},{"date":"2021-10-22","current":0.983772,"twenty":-4.306077,"median":-0.188207,"eighty":1.036368,"marketCap":3569125530},{"date":"2021-10-29","current":1.041097,"twenty":-4.303903,"median":-0.163857,"eighty":1.037057,"marketCap":3777099351},{"date":"2021-11-05","current":1.033875,"twenty":-4.303903,"median":-0.154011,"eighty":1.038157,"marketCap":3750897925},{"date":"2021-11-12","current":0.929008,"twenty":-4.303903,"median":-0.147568,"eighty":1.038157,"marketCap":3493071374},{"date":"2021-11-19","current":0.866789,"twenty":-4.303903,"median":-0.144043,"eighty":1.038157,"marketCap":3259128044},{"date":"2021-11-26","current":0.862727,"twenty":-4.303903,"median":-0.135656,"eighty":1.038157,"marketCap":3243853393},{"date":"2021-12-03","current":0.867003,"twenty":-4.303903,"median":-0.132933,"eighty":1.038157,"marketCap":3259931973},{"date":"2021-12-10","current":0.957018,"twenty":-4.303903,"median":-0.131401,"eighty":1.038157,"marketCap":3598386069},{"date":"2021-12-17","current":0.907627,"twenty":-4.303903,"median":-0.129637,"eighty":1.038157,"marketCap":3412678477},{"date":"2021-12-23","current":0.890522,"twenty":-4.303903,"median":-0.128172,"eighty":1.038157,"marketCap":3348364160},{"date":"2021-12-31","current":0.913186,"twenty":-4.301729,"median":-0.127623,"eighty":1.037925,"marketCap":3433580630},{"date":"2022-01-07","current":0.923235,"twenty":-4.299556,"median":-0.125931,"eighty":1.037693,"marketCap":3471365292},{"date":"2022-01-14","current":0.94312,"twenty":-4.297382,"median":-0.124796,"eighty":1.037461,"marketCap":3546130686},{"date":"2022-01-21","current":0.8747,"twenty":-4.297382,"median":-0.123683,"eighty":1.037461,"marketCap":3288873416},{"date":"2022-01-28","current":0.908482,"twenty":-4.297382,"median":-0.119566,"eighty":1.037461,"marketCap":3415894193},{"date":"2022-02-04","current":0.943334,"twenty":-4.297382,"median":-0.113467,"eighty":1.037461,"marketCap":3546934615},{"date":"2022-02-11","current":0.923235,"twenty":-4.297382,"median":-0.1075,"eighty":1.037461,"marketCap":3471365292},{"date":"2022-02-18","current":0.867431,"twenty":-4.297382,"median":-0.103418,"eighty":1.037461,"marketCap":3261539831},{"date":"2022-02-25","current":5.165989,"twenty":-4.297382,"median":-0.102228,"eighty":1.041064,"marketCap":3161585251},{"date":"2022-03-04","current":5.545557,"twenty":-4.297382,"median":-0.098825,"eighty":1.052583,"marketCap":3393881054},{"date":"2022-03-11","current":5.426929,"twenty":-4.297382,"median":-0.095621,"eighty":1.068156,"marketCap":3321280393},{"date":"2022-03-18","current":5.554651,"twenty":-4.297382,"median":-0.093491,"eighty":1.082113,"marketCap":3399446559},{"date":"2022-03-25","current":6.319709,"twenty":-4.297382,"median":-0.09226,"eighty":1.086639,"marketCap":3867661893},{"date":"2022-04-01","current":5.824146,"twenty":-4.297382,"median":-0.090741,"eighty":1.099785,"marketCap":3564377169},{"date":"2022-04-08","current":5.839472,"twenty":-4.297382,"median":-0.089288,"eighty":1.109119,"marketCap":3573757109},{"date":"2022-04-14","current":5.72069,"twenty":-4.297382,"median":-0.088072,"eighty":1.112087,"marketCap":3501062575},{"date":"2022-04-22","current":5.49079,"twenty":-4.297382,"median":-0.085936,"eighty":1.122881,"marketCap":3360363476},{"date":"2022-04-29","current":5.135721,"twenty":-4.297382,"median":-0.083434,"eighty":1.128826,"marketCap":3143061534},{"date":"2022-05-06","current":6.317189,"twenty":-4.297382,"median":-0.036731,"eighty":1.133261,"marketCap":3354427300},{"date":"2022-05-13","current":5.948771,"twenty":-4.297382,"median":-0.034058,"eighty":1.135997,"marketCap":3158797658},{"date":"2022-05-20","current":6.138828,"twenty":-4.297382,"median":-0.032649,"eighty":1.139111,"marketCap":3259717711},{"date":"2022-05-27","current":6.608122,"twenty":-4.297382,"median":-0.009371,"eighty":1.144584,"marketCap":3508912612},{"date":"2022-06-03","current":6.673911,"twenty":-4.297382,"median":-0.006676,"eighty":1.15065,"marketCap":3543846476},{"date":"2022-06-10","current":6.877125,"twenty":-4.297382,"median":-0.006101,"eighty":1.15921,"marketCap":3651753302},{"date":"2022-06-17","current":5.682692,"twenty":-4.297382,"median":-0.004946,"eighty":1.174147,"marketCap":3017509584},{"date":"2022-06-24","current":5.565734,"twenty":-4.299556,"median":-0.003394,"eighty":1.179463,"marketCap":2955404936},{"date":"2022-07-01","current":5.815732,"twenty":-4.299556,"median":-0.002473,"eighty":1.20687,"marketCap":3088153621},{"date":"2022-07-08","current":5.768949,"twenty":-4.299556,"median":-0.002422,"eighty":1.217882,"marketCap":3063311762},{"date":"2022-07-15","current":5.995555,"twenty":-4.299556,"median":-0.002351,"eighty":1.236563,"marketCap":3183639518},{"date":"2022-07-22","current":5.82158,"twenty":-4.299556,"median":-0.002233,"eighty":1.260937,"marketCap":3091258854},{"date":"2022-07-29","current":6.558415,"twenty":-4.299556,"median":-0.002174,"eighty":1.32151,"marketCap":3482518136},{"date":"2022-08-05","current":4.050534,"twenty":-4.299556,"median":-0.002096,"eighty":1.342826,"marketCap":3370044551},{"date":"2022-08-12","current":4.168309,"twenty":-4.299556,"median":-0.001964,"eighty":1.378712,"marketCap":3468032874},{"date":"2022-08-19","current":4.409293,"twenty":-4.299556,"median":-0.001896,"eighty":1.401773,"marketCap":3668532058},{"date":"2022-08-26","current":4.541563,"twenty":-4.299556,"median":-0.001796,"eighty":1.45064,"marketCap":3778580482},{"date":"2022-09-02","current":4.189146,"twenty":-4.299556,"median":-0.001178,"eighty":1.545904,"marketCap":3485369269},{"date":"2022-09-09","current":4.14113,"twenty":-4.299556,"median":0.57973,"eighty":1.621675,"marketCap":3445420184},{"date":"2022-09-16","current":3.922794,"twenty":-4.299556,"median":0.621294,"eighty":1.942057,"marketCap":3263764908},{"date":"2022-09-23","current":3.408211,"twenty":-4.299556,"median":0.642916,"eighty":2.736523,"marketCap":2835631313},{"date":"2022-09-30","current":3.481593,"twenty":-4.299556,"median":0.661656,"eighty":2.837464,"marketCap":2896685576},{"date":"2022-10-07","current":3.8476,"twenty":-4.299556,"median":0.671266,"eighty":2.906531,"marketCap":3201203133},{"date":"2022-10-14","current":3.623829,"twenty":-4.299556,"median":0.675351,"eighty":3.023758,"marketCap":3015025320},{"date":"2022-10-21","current":3.988023,"twenty":-4.299556,"median":0.681357,"eighty":3.122843,"marketCap":3318035364},{"date":"2022-10-28","current":3.952691,"twenty":-4.299556,"median":0.687603,"eighty":3.146065,"marketCap":3288638867},{"date":"2022-11-04","current":3.104166,"twenty":-4.299556,"median":0.696733,"eighty":3.174414,"marketCap":3585311802},{"date":"2022-11-11","current":3.033154,"twenty":-4.299556,"median":0.704181,"eighty":3.174414,"marketCap":3503293178},{"date":"2022-11-18","current":2.880016,"twenty":-4.299556,"median":0.715232,"eighty":3.174414,"marketCap":3326417998},{"date":"2022-11-25","current":2.915307,"twenty":-4.299556,"median":0.720758,"eighty":3.174414,"marketCap":3367179356},{"date":"2022-12-02","current":2.813845,"twenty":-4.299556,"median":0.737816,"eighty":3.174414,"marketCap":3249990451},{"date":"2022-12-09","current":2.542228,"twenty":-4.299556,"median":0.780821,"eighty":3.174414,"marketCap":2936273567},{"date":"2022-12-16","current":2.720575,"twenty":-4.299556,"median":0.785146,"eighty":3.174414,"marketCap":3142264003},{"date":"2022-12-23","current":2.741372,"twenty":-4.299556,"median":0.78875,"eighty":3.174414,"marketCap":3166284090},{"date":"2022-12-30","current":2.742002,"twenty":-4.299556,"median":0.793555,"eighty":3.174414,"marketCap":3167011971},{"date":"2023-01-06","current":2.651883,"twenty":-4.274667,"median":0.799561,"eighty":3.174414,"marketCap":3062924931},{"date":"2023-01-13","current":2.876234,"twenty":-4.219877,"median":0.829273,"eighty":3.174414,"marketCap":3322050709},{"date":"2023-01-20","current":2.982108,"twenty":-4.167301,"median":0.834376,"eighty":3.174414,"marketCap":3444334784},{"date":"2023-01-27","current":2.719945,"twenty":-4.084814,"median":0.845858,"eighty":3.174414,"marketCap":3141536122},{"date":"2023-02-03","current":2.569327,"twenty":-4.03426,"median":0.854679,"eighty":3.174414,"marketCap":2967572467},{"date":"2023-02-10","current":2.677721,"twenty":-4.008224,"median":0.863582,"eighty":3.174414,"marketCap":3092768068},{"date":"2023-02-17","current":2.493703,"twenty":-3.990086,"median":0.867003,"eighty":3.174414,"marketCap":2880226699},{"date":"2023-02-24","current":5.825747,"twenty":-3.906528,"median":0.87299,"eighty":3.191675,"marketCap":3052691405},{"date":"2023-03-03","current":5.999019,"twenty":-3.906528,"median":0.880046,"eighty":3.256836,"marketCap":3143485739},{"date":"2023-03-10","current":5.507855,"twenty":-3.906528,"median":0.883253,"eighty":3.347056,"marketCap":2886115972},{"date":"2023-03-17","current":4.791999,"twenty":-3.906528,"median":0.885824,"eighty":3.415786,"marketCap":2511007373},{"date":"2023-03-24","current":5.025358,"twenty":-3.906528,"median":0.893516,"eighty":3.480099,"marketCap":2633287460},{"date":"2023-03-31","current":5.223442,"twenty":-3.906126,"median":0.900969,"eighty":3.517215,"marketCap":2737083349},{"date":"2023-04-06","current":5.398461,"twenty":-3.906126,"median":0.906986,"eighty":3.537959,"marketCap":2828793414},{"date":"2023-04-14","current":5.525994,"twenty":-3.874187,"median":0.910407,"eighty":3.580043,"marketCap":2895620904},{"date":"2023-04-21","current":5.345548,"twenty":-3.063777,"median":0.913186,"eighty":3.644587,"marketCap":2801067115},{"date":"2023-04-28","current":5.331981,"twenty":-2.9157,"median":0.91789,"eighty":3.660877,"marketCap":2793957808},{"date":"2023-05-05","current":2.710499,"twenty":-2.83461,"median":0.923235,"eighty":3.676244,"marketCap":2710498650},{"date":"2023-05-12","current":2.780342,"twenty":-2.714739,"median":0.924416,"eighty":3.676244,"marketCap":2780342316},{"date":"2023-05-19","current":2.80574,"twenty":-2.651277,"median":0.929008,"eighty":3.676244,"marketCap":2805740013},{"date":"2023-05-26","current":2.804329,"twenty":-2.545508,"median":0.93136,"eighty":3.676244,"marketCap":2804329030},{"date":"2023-06-02","current":2.675224,"twenty":-2.467945,"median":0.93644,"eighty":3.676244,"marketCap":2675224071},{"date":"2023-06-09","current":2.91368,"twenty":-2.316342,"median":0.942265,"eighty":3.676244,"marketCap":2913680225},{"date":"2023-06-16","current":3.019504,"twenty":-2.192945,"median":0.944095,"eighty":3.676244,"marketCap":3019503962},{"date":"2023-06-23","current":3.033614,"twenty":-1.718042,"median":0.948848,"eighty":3.679803,"marketCap":3033613794},{"date":"2023-06-30","current":3.224802,"twenty":-1.017941,"median":0.957018,"eighty":3.683362,"marketCap":3224802012},{"date":"2023-07-07","current":3.126739,"twenty":-1.0117,"median":0.960652,"eighty":3.683362,"marketCap":3126738682},{"date":"2023-07-14","current":3.32216,"twenty":-1.004921,"median":0.967067,"eighty":3.683362,"marketCap":3322159850},{"date":"2023-07-21","current":3.467491,"twenty":-0.982348,"median":0.971585,"eighty":3.683362,"marketCap":3467491115},{"date":"2023-07-28","current":3.629754,"twenty":-0.970637,"median":0.996403,"eighty":3.683362,"marketCap":3629754179},{"date":"2023-08-04","current":3.965138,"twenty":-0.961085,"median":1.005213,"eighty":3.710729,"marketCap":3596379773},{"date":"2023-08-11","current":4.167386,"twenty":-0.952225,"median":1.01715,"eighty":3.727573,"marketCap":3779819278},{"date":"2023-08-18","current":4.15294,"twenty":-0.92449,"median":1.033875,"eighty":3.745954,"marketCap":3766716456},{"date":"2023-08-25","current":4.147618,"twenty":-0.908697,"median":1.038389,"eighty":3.807376,"marketCap":3761889101},{"date":"2023-09-01","current":4.245701,"twenty":-0.892518,"median":1.046068,"eighty":3.835822,"marketCap":3850850364},{"date":"2023-09-08","current":4.253304,"twenty":-0.869791,"median":1.057139,"eighty":3.859377,"marketCap":3857746586},{"date":"2023-09-15","current":4.409932,"twenty":-0.842442,"median":1.07614,"eighty":3.897468,"marketCap":3999808760},{"date":"2023-09-22","current":4.213006,"twenty":-0.808929,"median":1.083204,"eighty":3.922794,"marketCap":3821196610},{"date":"2023-09-29","current":4.397007,"twenty":-0.773875,"median":1.091536,"eighty":3.973528,"marketCap":3988085182},{"date":"2023-10-06","current":3.991749,"twenty":-0.70608,"median":1.106481,"eighty":3.985769,"marketCap":3620516550},{"date":"2023-10-13","current":4.141535,"twenty":-0.590904,"median":1.111225,"eighty":4.007048,"marketCap":3756372123},{"date":"2023-10-20","current":4.1978,"twenty":-0.536975,"median":1.119798,"eighty":4.025939,"marketCap":3807404166},{"date":"2023-10-27","current":4.029006,"twenty":-0.518093,"median":1.126535,"eighty":4.028558,"marketCap":3654308037},{"date":"2023-11-03","current":7.887836,"twenty":-0.278454,"median":1.132317,"eighty":4.047258,"marketCap":3620516550},{"date":"2023-11-10","current":7.576588,"twenty":-0.034677,"median":1.134676,"eighty":4.075326,"marketCap":3477654048},{"date":"2023-11-17","current":7.666287,"twenty":-0.0331,"median":1.137946,"eighty":4.100348,"marketCap":3518825959},{"date":"2023-11-24","current":7.735057,"twenty":-0.031186,"median":1.139866,"eighty":4.114893,"marketCap":3550391090},{"date":"2023-12-01","current":7.655823,"twenty":-0.007262,"median":1.146471,"eighty":4.140768,"marketCap":3514022569},{"date":"2023-12-08","current":7.343371,"twenty":-0.006175,"median":1.153272,"eighty":4.15294,"marketCap":3370607081},{"date":"2023-12-15","current":7.699177,"twenty":-0.005661,"median":1.164163,"eighty":4.166853,"marketCap":3533922326},{"date":"2023-12-21","current":8.083389,"twenty":-0.004329,"median":1.174914,"eighty":4.173165,"marketCap":3710275343},{"date":"2023-12-29","current":8.213452,"twenty":-0.002728,"median":1.179572,"eighty":4.184722,"marketCap":3769974613},{"date":"2024-01-05","current":7.787381,"twenty":-0.002424,"median":1.200531,"eighty":4.190957,"marketCap":3574408038},{"date":"2024-01-12","current":7.663298,"twenty":-0.002376,"median":1.215841,"eighty":4.213006,"marketCap":3517453562},{"date":"2024-01-19","current":7.540709,"twenty":-0.002348,"median":1.23323,"eighty":4.21852,"marketCap":3461185284},{"date":"2024-01-26","current":7.703662,"twenty":-0.00223,"median":1.25325,"eighty":4.229765,"marketCap":3535980922},{"date":"2024-02-02","current":7.107163,"twenty":-0.00217,"median":1.308157,"eighty":4.245701,"marketCap":3262187716},{"date":"2024-02-09","current":8.022094,"twenty":-0.002082,"median":1.341101,"eighty":4.269271,"marketCap":3682141204},{"date":"2024-02-16","current":8.139367,"twenty":-0.001939,"median":1.357573,"eighty":4.305767,"marketCap":3735969362},{"date":"2024-02-23","current":8.27369,"twenty":-0.001896,"median":1.390517,"eighty":4.333899,"marketCap":3797623594},{"date":"2024-03-01","current":6.407884,"twenty":-0.001842,"median":1.402185,"eighty":4.370203,"marketCap":3614046387},{"date":"2024-03-08","current":6.000098,"twenty":-0.001842,"median":1.402185,"eighty":4.398139,"marketCap":3384055319},{"date":"2024-03-15","current":6.635114,"twenty":-0.001842,"median":1.402185,"eighty":4.486299,"marketCap":3742204060},{"date":"2024-03-22","current":6.837155,"twenty":-0.001842,"median":1.402185,"eighty":4.590123,"marketCap":3856155238},{"date":"2024-03-28","current":6.696949,"twenty":-0.001842,"median":1.402185,"eighty":4.889684,"marketCap":3777079302},{"date":"2024-04-05","current":6.605511,"twenty":-0.001842,"median":1.400126,"eighty":5.026714,"marketCap":3725508039},{"date":"2024-04-12","current":6.893237,"twenty":-0.001842,"median":1.400126,"eighty":5.165989,"marketCap":3887785613},{"date":"2024-04-19","current":6.545771,"twenty":-0.001842,"median":1.400126,"eighty":5.223442,"marketCap":3691814813},{"date":"2024-04-26","current":6.737182,"twenty":-0.001842,"median":1.402185,"eighty":5.288565,"marketCap":3799770657},{"date":"2024-05-03","current":6.278771,"twenty":-0.001842,"median":1.402185,"eighty":5.337699,"marketCap":3541226726},{"date":"2024-05-10","current":13.595091,"twenty":-0.001842,"median":1.402185,"eighty":5.365367,"marketCap":3439558041},{"date":"2024-05-17","current":13.340471,"twenty":-0.001842,"median":1.402185,"eighty":5.398279,"marketCap":3375139142},{"date":"2024-05-24","current":12.657872,"twenty":-0.001842,"median":1.402185,"eighty":5.428033,"marketCap":3202441667},{"date":"2024-05-31","current":12.76893,"twenty":-0.001842,"median":1.402185,"eighty":5.474551,"marketCap":3230539272},{"date":"2024-06-07","current":12.771639,"twenty":-0.001842,"median":1.402185,"eighty":5.522366,"marketCap":3231224579},{"date":"2024-06-14","current":13.283588,"twenty":-0.001842,"median":1.400126,"eighty":5.545711,"marketCap":3360747685},{"date":"2024-06-21","current":13.440694,"twenty":-0.00185,"median":1.396694,"eighty":5.56864,"marketCap":3400495517},{"date":"2024-06-28","current":14.203543,"twenty":-0.001873,"median":1.390517,"eighty":5.588625,"marketCap":3593496288},{"date":"2024-07-05","current":18.737699,"twenty":-0.001873,"median":1.390517,"eighty":5.623622,"marketCap":4740637844},{"date":"2024-07-12","current":18.734158,"twenty":-0.001873,"median":1.390517,"eighty":5.681579,"marketCap":4739742032},{"date":"2024-07-15","current":18.199504,"twenty":-0.001873,"median":1.390517,"eighty":5.682628,"marketCap":4604474399},{"date":"2024-08-02","current":17.324936,"twenty":-0.001911,"median":1.346824,"eighty":5.705155,"marketCap":4383208801},{"date":"2024-08-09","current":26.336533,"twenty":-0.001911,"median":1.353001,"eighty":5.730738,"marketCap":4319191489},{"date":"2024-08-16","current":27.446127,"twenty":-0.001911,"median":1.366496,"eighty":5.752282,"marketCap":4501164861},{"date":"2024-08-23","current":27.935654,"twenty":-0.001911,"median":1.402185,"eighty":5.768949,"marketCap":4581447230},{"date":"2024-08-30","current":28.947342,"twenty":-0.001911,"median":1.534648,"eighty":5.815918,"marketCap":4747364128},{"date":"2024-09-06","current":26.798864,"twenty":-0.001911,"median":1.621812,"eighty":5.830215,"marketCap":4395013727},{"date":"2024-09-13","current":26.532344,"twenty":-0.001911,"median":2.339797,"eighty":5.906847,"marketCap":4351304437},{"date":"2024-09-20","current":28.69714,"twenty":-0.001911,"median":2.536241,"eighty":5.949941,"marketCap":4706330917},{"date":"2024-09-27","current":27.065384,"twenty":-0.001911,"median":2.572163,"eighty":5.993801,"marketCap":4438723018},{"date":"2024-10-04","current":29.175788,"twenty":-0.001911,"median":2.598946,"eighty":6.004674,"marketCap":4784829234},{"date":"2024-10-11","current":28.196735,"twenty":-0.001911,"median":2.632346,"eighty":6.084735,"marketCap":4624264494},{"date":"2024-10-18","current":28.457816,"twenty":-0.001911,"median":2.652829,"eighty":6.188884,"marketCap":4667081758},{"date":"2024-10-25","current":28.909268,"twenty":-0.001911,"median":2.676473,"eighty":6.29292,"marketCap":4741119943},{"date":"2024-10-31","current":28.457816,"twenty":-0.001911,"median":2.700529,"eighty":6.318197,"marketCap":4667081758},{"date":"2024-11-08","current":9.769816,"twenty":-0.001911,"median":2.720575,"eighty":6.403954,"marketCap":5187772215},{"date":"2024-11-15","current":10.08759,"twenty":-0.001911,"median":2.730028,"eighty":6.445337,"marketCap":5356510077},{"date":"2024-11-22","current":10.289652,"twenty":-0.001911,"median":2.745773,"eighty":6.495297,"marketCap":5463805348},{"date":"2024-11-29","current":10.217117,"twenty":-0.001911,"median":2.769054,"eighty":6.509101,"marketCap":5425289097},{"date":"2024-12-06","current":9.553937,"twenty":-0.001911,"median":2.793041,"eighty":6.54466,"marketCap":5073140515},{"date":"2024-12-13","current":9.540121,"twenty":-0.001911,"median":2.802213,"eighty":6.559607,"marketCap":5065804086},{"date":"2024-12-20","current":8.804405,"twenty":-0.001911,"median":2.809973,"eighty":6.611052,"marketCap":4675139252},{"date":"2024-12-27","current":8.8424,"twenty":-0.001911,"median":2.83149,"eighty":6.63564,"marketCap":4695314432},{"date":"2025-01-03","current":8.98229,"twenty":-0.001911,"median":2.859849,"eighty":6.695486,"marketCap":4769595773},{"date":"2025-01-10","current":9.056419,"twenty":-0.001912,"median":2.878125,"eighty":6.715023,"marketCap":4808958516},{"date":"2025-01-17","current":9.287002,"twenty":-0.001912,"median":2.910877,"eighty":6.768152,"marketCap":4931398273},{"date":"2025-01-24","current":9.164828,"twenty":-0.001912,"median":2.92539,"eighty":6.812937,"marketCap":4866523476},{"date":"2025-01-31","current":8.779375,"twenty":-0.001912,"median":2.958773,"eighty":6.905886,"marketCap":4661848062},{"date":"2025-02-07","current":8.251098,"twenty":-0.001912,"median":2.977067,"eighty":7.022037,"marketCap":4381333096},{"date":"2025-02-14","current":7.96545,"twenty":-0.001912,"median":3.016876,"eighty":7.290747,"marketCap":4229653994},{"date":"2025-02-21","current":8.393922,"twenty":-0.001912,"median":3.041727,"eighty":7.484796,"marketCap":4457172647},{"date":"2025-02-28","current":7.688406,"twenty":-0.001893,"median":3.115452,"eighty":7.51948,"marketCap":4082543540},{"date":"2025-03-07","current":9.891447,"twenty":-0.001794,"median":3.192349,"eighty":7.555659,"marketCap":3719184042},{"date":"2025-03-14","current":10.152193,"twenty":-0.001042,"median":3.260077,"eighty":7.584063,"marketCap":3817224529},{"date":"2025-03-21","current":10.724385,"twenty":0.607359,"median":3.33664,"eighty":7.655823,"marketCap":4032368932},{"date":"2025-03-28","current":10.680928,"twenty":0.634508,"median":3.474546,"eighty":7.696187,"marketCap":4016028850},{"date":"2025-04-04","current":9.797289,"twenty":0.645015,"median":3.602945,"eighty":7.709642,"marketCap":3683780532},{"date":"2025-04-11","current":8.073821,"twenty":0.663604,"median":3.657801,"eighty":7.734459,"marketCap":3035756810},{"date":"2025-04-17","current":8.348654,"twenty":0.671387,"median":3.719197,"eighty":7.75509,"marketCap":3139094008},{"date":"2025-04-25","current":8.524644,"twenty":0.677063,"median":3.80955,"eighty":7.787381,"marketCap":3205266074},{"date":"2025-05-02","current":8.536698,"twenty":0.682705,"median":3.875685,"eighty":7.879412,"marketCap":3209798407}],"updateTime":1746386896524}}}